European Pharmaceutical Review

MAY 23, 2024

Last month, CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) was the first BCMA-targeted CAR-T cell therapy to be approved for second-line treatment of multiple myeloma by the US Food and Drug Administration (FDA). CAR T Cells: Engineering Immune Cells to Treat Cancer [Internet]. 2 Why does CARVYKTI have potential in multiple myeloma?

Medical Schools 110

Medical Schools FDA Chemotherapy Immunization 110

STAT

MARCH 6, 2023

“I’m slowly running out of options,” said Young, 62, who in November began   receiving   a five-month series of shots at a clinic near her San Francisco home; the vaccine is designed to teach her immune cells to recognize and combat tumors. “People come to this thinking they will be cured.”

Vaccines 98

Vaccines FDA Immunization Chemotherapy 98

European Pharmaceutical Review

DECEMBER 28, 2023

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. Many cancer patients, however, lack a functional innate immune system, and do not have enough functional NK cells. Dr Harstrick received his M.D.

Immunization 84

Immunization Chemotherapy Medical Schools FDA 84

pharmaphorum

SEPTEMBER 16, 2022

The FDA granted lebrikizumab Fast Track designation in December 2019. Almirall has previously found state-of-the-art therapies for immune-related inflammatory diseases such as hidradenitis suppurativa, alopecia areata, psoriasis, and vitiligo.

Medical Schools 100

Medical Schools Hospitals Dosage Labelling 100

PharmaShots

MAY 19, 2023

Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US Date: May 19, 2023 | Tags: Alimera, EyePoint Pharmaceuticals, Yutiq, Iluvien, chronic non-infectious uveitis, US, Pharma Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A Date: May 19, 2023 | Tags: Sobi, Efanesoctocog Alfa, (..)

Medical Schools 40

Medical Schools FDA Immunization Vaccines 40

pharmaphorum

JANUARY 8, 2021

The FDA issued a statement regarding dosing schedules on 4 January 2021. “We Until vaccine manufacturers have data and science supporting a change, we continue to strongly recommend that health care providers follow the FDA-authorized dosing schedule for each COVID-19 vaccine.”. Industry support.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59

pharmaphorum

JANUARY 8, 2021

The FDA issued a statement regarding dosing schedules on 4 January 2021. “We Until vaccine manufacturers have data and science supporting a change, we continue to strongly recommend that health care providers follow the FDA-authorized dosing schedule for each COVID-19 vaccine.”. Industry support.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59